Seizure control and adverse outcomes of lamotrigine use during pregnancy: A systematic review and meta-analysis
Epilepsy & Behavior · 2024
DOI: 10.1016/j.yebeh.2024.109924 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Epilepsy & Behavior, 2024. Verfasst von Xin Wan und 5 weiteren Autor:innen. Beteiligte Einrichtung: First School of Clinical Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Anticonvulsants, Lamotrigine, Pregnancy Complications, Seizures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: This review aims to summarize existing evidence on the adverse pregnancy outcomes and seizure control effects of using lamotrigine (LTG) monotherapy in pregnancy women with epilepsy (WWE) during pregnancy. METHODS: A comprehensive search was conducted in various databases including Cochrane, Web of Science, CBM, PubMed, Embase, CNKI, and Pregnancy Registration Center databases to identify relevant studies. The search was concluded up to January 2024. Studies comparing LTG with other antiseizure medications (ASMs) for treating epilepsy in pregnant women were included, with no language or regional restrictions. RESULTS: A total of 19 studies were included for analysis, with 16 studies reporting adverse pregnancy outcomes and 6 studies reporting seizure control outcomes. Meta-analysis showed that compared to monotherapy with carbamazepine (CBZ), sodium valproate (VPA), and levetiracetam (LEV), LTG monotherapy had a slightly weaker ability to control seizures during pregnancy, with ORs and 95 %CIs of 0.65 (0.57-0.75; CBZ), 0.50 (0.32-0.79; VPA), and 0.55 (0.36-0.84; LEV). Regarding adverse pregnancy outcomes, the occurrence rate of LTG monotherapy was significantly lower than that of CBZ, VPA, phenytoin (PHT), and phenobarbital (PHB), with ORs and 95 %CIs ranging from 0.30 (0.25-0.35; VPA) to 0.68 (0.56-0.81; CBZ). CONCLUSION: Based on meta-analysis, LTG and LEV appear to be preferred medications for controlling seizures during pregnancy. This review provides further support for the use of LTG monotherapy in pregnant WWE, building upon existing evidence for clinical practitioners.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First School of Clinical Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Psychosomatic Medicine, The 1(st) Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Child and Adolescent Psychology, Third Fuzhou Jiangxi Hospital, Fuzhou, China.
- First School of Clinical Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China; Department of Psychosomatic Medicine, The 1(st) Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nancha…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wan, X., Wu, Y., Zou, Q., Yuan, B., Huang, L., & Hu, M. (2024). Seizure control and adverse outcomes of lamotrigine use during pregnancy: A systematic review and meta-analysis. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2024.109924
Vancouver
Wan X, Wu Y, Zou Q, Yuan B, Huang L, Hu M. Seizure control and adverse outcomes of lamotrigine use during pregnancy: A systematic review and meta-analysis. Epilepsy & Behavior. 2024. doi:10.1016/j.yebeh.2024.109924
BibTeX
@article{Wan2024,
author = {Wan, Xin and Wu, Yunhong and Zou, Qing and Yuan, Bin and Huang, Liping and Hu, Maorong},
title = {Seizure control and adverse outcomes of lamotrigine use during pregnancy: A systematic review and meta-analysis},
journal = {Epilepsy & Behavior},
year = {2024},
doi = {10.1016/j.yebeh.2024.109924}
}
EUVIMED